Search Results | DrugBank Online

Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

Investigational

Lidorestat

Investigational

2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide

Experimental

1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA

Experimental

Displaying drugs 9126 - 9150 of 9970 in total

Advanced Filter

Filter by Group

Filter by Market Availability

(R)-methylmalonyl-CoA

Malonyl-CoA

Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine

Darinaparsin

Acetyl hexapeptide-3

L-gulonic acid 6-phosphate

Nanaomycin D

Phosphoaspartate

Di-Stearoyl-3-Sn-Phosphatidylethanolamine

D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide

1,2-Di-N-Pentanoyl-Sn-Glycero-3-Dithiophosphocholine

3-Methyl-5-Sulfo-Pyrrolidine-2-Carboxylic Acid

Diundecyl Phosphatidyl Choline

Difluoromethionine

2-Amino-3-Hydroxy-3-Phosphonooxy-Propionic Acid

3-Chloro-4-Hydroxyphenylglycine

2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid

Mdl-29951

Di-Stearoyl-3-Sn-Phosphatidylcholine

N-Methylleucine

Fradafiban

Tesaglitazar

Lidorestat

2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide

1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA